Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 107Xls
2D Structure
Also known as: 66108-95-0, Omnipaque, Nycodenz, Exypaque, Iohexolum, Omnipaque 240
Molecular Formula
C19H26I3N3O9
Molecular Weight
821.1  g/mol
InChI Key
NTHXOOBQLCIOLC-UHFFFAOYSA-N
FDA UNII
4419T9MX03

An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Iohexol is a Radiographic Contrast Agent. The mechanism of action of iohexol is as a X-Ray Contrast Activity.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
5-[acetyl(2,3-dihydroxypropyl)amino]-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
2.1.2 InChI
InChI=1S/C19H26I3N3O9/c1-8(29)25(4-11(32)7-28)17-15(21)12(18(33)23-2-9(30)5-26)14(20)13(16(17)22)19(34)24-3-10(31)6-27/h9-11,26-28,30-32H,2-7H2,1H3,(H,23,33)(H,24,34)
2.1.3 InChI Key
NTHXOOBQLCIOLC-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
2.2 Other Identifiers
2.2.1 UNII
4419T9MX03
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Compound 545

2. Exypaque

3. Iohexol 350

4. Nycodenz

5. Omnipaque

2.3.2 Depositor-Supplied Synonyms

1. 66108-95-0

2. Omnipaque

3. Nycodenz

4. Exypaque

5. Iohexolum

6. Omnipaque 240

7. Omnipaque 70

8. Omnipaque 140

9. Omnipaque 180

10. Omnipaque 210

11. Omnipaque 300

12. Omnipaque 350

13. Win 39424

14. Oraltag

15. Win-39424

16. Chebi:31709

17. N,n'-bis(2,3-dihydroxypropyl)-5-(n-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide

18. 5-[acetyl(2,3-dihydroxypropyl)amino]-1-n,3-n-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide

19. 5-[acetyl(2,3-dihydroxypropyl)amino]-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide

20. N1,n3-bis(2,3-dihydroxypropyl)-5-(n-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide

21. 4419t9mx03

22. Nsc-759636

23. Ncgc00166000-01

24. Dsstox_cid_3157

25. 5-(n-2,3-dihydroxypropylacetamido)-2,4,6-triiodo-n,n'-bis(2,3-dihydroxypropyl)isophthalamide

26. Dsstox_rid_76895

27. Dsstox_gsid_23157

28. 1,3-benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-

29. Histodenz

30. Iohexolum [inn-latin]

31. 1,3-benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-n1,n3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-

32. 5-[acetyl(2,3-dihydroxypropyl)amino]-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide

33. 5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodo-n,n'-bis(2,3-dihydroxypropyl)isophthalamide

34. Smr000857075

35. Einecs 266-164-2

36. Brn 2406632

37. Unii-4419t9mx03

38. Omnipaque (tn)

39. 1,3-benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-

40. N,n'-bis(2,3-dihydroxypropyl)-5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodoisophthalamide

41. Prestwick_802

42. Cas-66108-95-0

43. Iohexol [usan:usp:inn:ban:jan]

44. Iohexol [vandf]

45. Iohexol [usan]

46. Iohexol [inn]

47. Iohexol [jan]

48. Iohexol [mi]

49. Iohexol [mart.]

50. Prestwick0_000512

51. Prestwick1_000512

52. Prestwick2_000512

53. Prestwick3_000512

54. Iohexol [usp-rs]

55. Iohexol [who-dd]

56. Iohexol [who-ip]

57. Nycodenz;omnipaque;exypaque

58. Ec 266-164-2

59. Iohexol, Analytical Standard

60. Schembl26501

61. Bspbio_000463

62. Mls001332585

63. Mls001332586

64. Mls002153854

65. Iohexol (jp17/usp/inn)

66. Iohexol [ep Impurity]

67. Iohexol [orange Book]

68. Spbio_002384

69. Iohexol [ep Monograph]

70. Bpbio1_000511

71. Iohexol [usp Monograph]

72. Chembl1200455

73. Dtxsid6023157

74. Bcbcmap01_000051

75. Iohexolum [who-ip Latin]

76. Hms1569h05

77. Hms2096h05

78. Hms2235d07

79. Hms3369o04

80. Hms3713h05

81. Albb-028959

82. Amy21804

83. Bcp31800

84. Hy-b0594

85. Tox21_112286

86. Bdbm50247977

87. Iohexol (mixture Of Isomers)

88. Mfcd00077732

89. S4531

90. Akos015895399

91. Tox21_112286_1

92. Ac-1934

93. Ccg-220512

94. Db01362

95. Nsc 759636

96. Smp1_000152

97. Ncgc00166000-02

98. Ncgc00166000-04

99. As-12699

100. Ft-0627276

101. I0903

102. D01817

103. D91214

104. Histodenz(tm), Nonionic Density Gradient Medium

105. 108i950

106. A835339

107. Q410683

108. Sr-01000838892

109. Sr-01000838892-2

110. Iohexol, European Pharmacopoeia (ep) Reference Standard

111. Iohexol, United States Pharmacopeia (usp) Reference Standard

112. 5-(n-dhp-acetamido)-2,4,6-triiodo-n,n'-b Is-dhp-isophthalami

113. Iohexol, Pharmaceutical Secondary Standard; Certified Reference Material

114. Iohexol For Peak Identification, European Pharmacopoeia (ep) Reference Standard

115. 1,3-benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-n,n'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo

116. 1-n,3-n-bis(2,3-dihydroxypropyl)-5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide

117. 5-[acetyl(2,3-dihydroxypropyl)amino]-n1,n3-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide

118. N1,n3-bis(2,3-dihydroxypropyl)-5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide

119. N1,n3-bis[2,3-bis(oxidanyl)propyl]-5-[2,3-bis(oxidanyl)propyl-ethanoyl-amino]-2,4,6-tris(iodanyl)benzene-1,3-dicarboxamide

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 821.1 g/mol
Molecular Formula C19H26I3N3O9
XLogP3-3
Hydrogen Bond Donor Count8
Hydrogen Bond Acceptor Count9
Rotatable Bond Count12
Exact Mass820.8803 g/mol
Monoisotopic Mass820.8803 g/mol
Topological Polar Surface Area200 Ų
Heavy Atom Count34
Formal Charge0
Complexity653
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count3
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameOmnipaque 180
PubMed HealthIohexol (Injection)
Drug ClassesRadiological Non-Ionic Contrast Media
Active IngredientIohexol
Dosage FormSolution
RouteInjection, oral, rectal
Strength38.8%
Market StatusPrescription
CompanyGe Healthcare

2 of 4  
Drug NameOmnipaque 240
Active IngredientIohexol
Dosage FormSolution
RouteInjection, oral, rectal
Strength51.8%
Market StatusPrescription
CompanyGe Healthcare

3 of 4  
Drug NameOmnipaque 180
PubMed HealthIohexol (Injection)
Drug ClassesRadiological Non-Ionic Contrast Media
Active IngredientIohexol
Dosage FormSolution
RouteInjection, oral, rectal
Strength38.8%
Market StatusPrescription
CompanyGe Healthcare

4 of 4  
Drug NameOmnipaque 240
Active IngredientIohexol
Dosage FormSolution
RouteInjection, oral, rectal
Strength51.8%
Market StatusPrescription
CompanyGe Healthcare

4.2 Drug Indication

Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.


5.2 MeSH Pharmacological Classification

Contrast Media

Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
IOHEXOL
5.3.2 FDA UNII
4419T9MX03
5.3.3 Pharmacological Classes
X-Ray Contrast Activity [MoA]; Radiographic Contrast Agent [EPC]
5.4 ATC Code

V08AB02

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


V - Various

V08 - Contrast media

V08A - X-ray contrast media, iodinated

V08AB - Watersoluble, nephrotropic, low osmolar x-ray contrast media

V08AB02 - Iohexol


5.5 Absorption, Distribution and Excretion

Absorption

Small amounts are absorbed through the bladder via intravesical instillation. Following intrauterine instillation, the majority of the medium within the uterine cavity is discharged into the vagina immediately upon termination of procedure. However, any medium retained in the uterine or peritoneal cavity is absorbed systemically within 60 minutes. May not be absorbed for up to 24 hours if tubes are obstructed and dilated.


Route of Elimination

Iohexol is absorbed from cerebrospinal fluid (CSF) into the bloodstream and is eliminated by renal excretion. No significant metabolism, deiodination, or biotransformation occurs.


Volume of Distribution

350-849 mL/kg


Clearance

109 mL/min [Adult patients receiving 16-18 ml of iohexol (180 mgI/mL) by lumbar intrathecal injection]


5.6 Biological Half-Life

Intrathecal half-life is 3.4 hours (mean). Intravascular is approximately 2 hours (with normal renal function).


5.7 Mechanism of Action

Organic iodine compounds block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays. After intrathecal administration into the subarachnoid space, diffusion of iohexol in the CSF allows the visualization of the subarachnoid spaces of the head and spinal canal. After intravascular administration, iohexol makes opaque those vessels in its path of flow, allowing visualization of the internal structures until significant hemodilution occurs.